|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.8749 - 0.9600|
|52 Week Range||0.1710 - 1.3000|
|Beta (5Y Monthly)||3.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, BC / ACCESSWIRE / February 26, 2021 /Core One Labs Inc. (CSE:COOL), (OTC PINK:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the "Company" or "Core One") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials.
VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company" or "Core One") a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a definitive agreement to acquire (the "Transaction") Ketamine Infusion Centers of Texas Inc.
VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) ("Core One" the "Company") is pleased with the tremendous turnout on the International Investors' Call held earlier today.